Sign Out
Studies with single or repeated doses of nicergoline have shown that nicergoline may lower systolic blood pressure and to a far lesser degree, diastolic blood pressure in normotensive patients and patients with elevated blood pressures. These effects can be variable, as other studies have not demonstrated changes in systolic or diastolic blood pressure.
Sympathomimetics agonists (alpha and beta) should be used with caution in patients receiving nicergoline (see Interactions).
It should be administered with caution to patients with hyperuricemia or a history of gout and/or during concomitant treatment with drugs that may influence the metabolism and excretion of uric acid (see Adverse Reactions).
Fibrosis (e.g., pulmonary, cardiac, cardiac valvular and retroperitoneal) has been associated with the use of some ergot alkaloids with agonist activity at the serotonin 5HT 2β receptor.
The symptoms of ergotism (including nausea, vomiting, diarrhea, abdominal pain and peripheral vasoconstriction) have been reported with the ingestion of some ergot alkaloids and their derivatives. Clinicians and prescribers should be aware of the signs and symptoms of ergot overdosing prior to prescribing this class of medications.
Effects on ability to drive and use machines: Although the clinical effects of nicergoline include an improvement of alertness and concentration, its effects on the ability to drive and operate machines have not been specifically studied. Caution should be used, considering the underlying disease of the patients. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or somnolence may occur (see Adverse Reactions).
